Maia Biotechnology, Inc. Announces $6.2 Million Financing To Advance Targeted Immuno-Oncology Studies
Maia Biotechnology, Inc. Announces $6.2 Million Financing To Advance Targeted Immuno-Oncology Studies
10/14/21, 12:00 PM
Location
chicagoMoney raised
$6.2 million
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has raised an additional $6.2 million in an equity offering at $8/share. The proceeds of the financing will advance the company’s programs and will support the initiation of a Phase 2 clinical trial (THIO-101) evaluating the administration of THIO followed by cemiplimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The THIO-101 trial is expected to begin this year.
Company Info
Location
chicago, illinois, united states
Additional Info
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.